Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Singapore flag Singapore · Delayed Price · Currency is SGD · Price in USD
2.870
+0.050 (1.77%)
Oct 10, 2025, 5:04 PM SGT
1.77%
Market Cap5.28B
Revenue (ttm)1.07B
Net Income (ttm)621.98M
Shares Outn/a
EPS (ttm)0.81
PE Ratio8.50
Forward PEn/a
Dividend0.23 (7.90%)
Ex-Dividend DateJun 25, 2025
Volume101,500
Average Volume119,745
Open2.830
Previous Close2.820
Day's Range2.810 - 2.900
52-Week Range1.990 - 3.130
Betan/a
RSI47.45
Earnings DateOct 31, 2025

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ... [Read more]

Sector Healthcare
Founded 1981
Employees 4,619
Stock Exchange Singapore Exchange
Ticker Symbol T14
Full Company Profile

Financial Performance

In 2024, SGX:T14's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.